L3VLUP
ProSign in

RXRX · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

RXRXGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • RXRX
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterRXRXGILD
Q3 2020none listed holders, n.a.25 holders, $14.2bn
Q4 2020none listed holders, n.a.27 holders, $13.4bn
Q1 2021none listed holders, n.a.24 holders, $14.5bn
Q2 20212 holders, $763m18 holders, $14.9bn
Q3 20212 holders, $567m20 holders, $16.4bn
Q4 20212 holders, $417m20 holders, $16.8bn
Q1 20222 holders, $178m28 holders, $13.2bn
Q2 20222 holders, $193m26 holders, $13.6bn
Q3 20222 holders, $266m24 holders, $13.3bn
Q4 20222 holders, $215m32 holders, $21.1bn
Q1 20232 holders, $192m27 holders, $21.8bn
Q2 20232 holders, $223m24 holders, $20.7bn
Q3 20232 holders, $240m24 holders, $20.0bn
Q4 20232 holders, $442m22 holders, $21.5bn
Q1 20242 holders, $485m30 holders, $20.3bn
Q2 20243 holders, $415m28 holders, $18.5bn
Q3 20243 holders, $387m29 holders, $24.2bn
Q4 20242 holders, $387m28 holders, $25.9bn
Q1 20253 holders, $315m33 holders, $32.0bn
Q2 20252 holders, $289m27 holders, $30.9bn
Q3 20252 holders, $281m23 holders, $29.4bn
Q4 20252 holders, $250m25 holders, $34.3bn
Q1 20262 holders, $196m25 holders, $38.5bn
Q2 20262 holders, $238m26 holders, $34.2bn
RXRX

Recursion Pharmaceuticals Inc

Holders
3
Reported value
$315m
Buyers
2
Sellers
1

Breadth +1 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
33
Reported value
$32.0bn
Buyers
21
Sellers
12

Breadth +9 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q1 2025

Among the 35 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only RXRX (2)

ARK Investment Management LLC, Baillie Gifford & Co

Only GILD (32)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Element Capital Management LLC, ExodusPoint Capital Management LP, Fidelity (FMR LLC), Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Point72 Asset Management LP, and 7 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →